Publicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (15)

2018

  1. Role of multimeric analysis of von willebrand factor (VWF) in von willebrand disease (VWD) diagnosis: Lessons from the PCM-EVW-ES Spanish project

    PLoS ONE, Vol. 13, Núm. 6

2017

  1. Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients

    Haematologica, Vol. 102, Núm. 12, pp. 2005-2014

  2. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970

2016

  1. Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm

    Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50

2015

  1. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  2. Use of eltrombopag after romiplostim in primary immune thrombocytopenia

    British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116

2010

  1. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

    Haematologica, Vol. 95, Núm. 11, pp. 1913-1920

2003

  1. Immunophenotypic analysis of Waldenstrom's macroglobulinemia

    Seminars in Oncology, Vol. 30, Núm. 2, pp. 187-195

1998

  1. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma

    Thrombosis Research, Vol. 89, Núm. 2, pp. 59-64

1995

  1. Efficacy of D-dimer and total fibrin degradation products evaluation in suspected pulmonary embolism

    Respiration, Vol. 62, Núm. 5, pp. 258-262

1994

  1. CONTROL DE LA ANTICOAGULACION ORAL EN SANGRE CAPILAR

    Sangre, Vol. 39, Núm. 4, pp. 257-260

  2. High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA

    Thrombosis Research, Vol. 73, Núm. 2, pp. 109-115

  3. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis

    Thrombosis Research, Vol. 75, Núm. 5, pp. 513-520

1993

  1. Analysis of the fibrinolytic response on disseminated intravascular coagulation

    Sangre, Vol. 38, Núm. 3, pp. 221-224

  2. ESTADO ACTUAL DE LA TROMBOLISIS. NECESIDAD DE LA TERAPEUTIFCA ANTITROMBOTICA COADYUVANTE

    Revista Clinica Espanola, Vol. 193, Núm. 2, pp. 88-92